Company: DARE
Filing Date: 2025-04-11
Form Type: 8-K
Source: 0001641172-25-003887
Chunk: 1

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-11
Form: 8-K
Item: Item 8.01
Chunk 1
---
 required thereby. While we are actively pursuing a range
of initiatives aimed at executing against our Plan, no assurances can be given that we will be successful in doing so or that we will
satisfy either the Stockholders’ Equity Rule or the Minimum MVLS Rule by August 12, 2025. If we fail to execute on our Plan to the
Panel’s satisfaction and remain non-compliant with Nasdaq’s continued listing requirements, the Panel may take action to delist
our common stock after April 30, 2025, even though the Panel granted us conditional continued listing until August 12, 2025. As is customary,
the Panel also reserved the right to reconsider the terms of the extension it granted based on any event, condition or circumstance that
exists or develops that would, in the opinion of the Panel, make continued listing of our common stock inadvisable or unwarranted. See
the risk factor titled, “ If we fail to regain and maintain compliance with the continued listing requirements of The Nasdaq Capital
Market, our common stock could be suspended and delisted, which could, among other things, limit demand for our common stock, substantially
impair our ability to raise additional capital and have an adverse effect on the market price of, and the efficiency of the trading market
for, our common stock,” and our other risk factors in Item 1A of Part I of our annual report on Form 10-K filed with the Securities
and Exchange Commission (the “ SEC”) on March 31, 2025.

Forward-Looking Statements